Dis­ap­point­ing PhI­II re­sults dash As­traZeneca's hopes of re­viv­ing a tar­nished can­cer drug through Lyn­parza com­bo

Bare­ly a year af­ter a team at Yale tried to make sense of some un­ex­pect­ed Phase II re­sults around an ovar­i­an can­cer drug that As­traZeneca had all but shelved, Phase III in­ves­ti­ga­tors are re­port­ing that it might all have been a mi­rage.

De­spite the el­e­vat­ed ex­pec­ta­tions, adding cedi­ranib to Lyn­parza — As­traZeneca’s Mer­ck-part­nered star PARP in­hibitor — did not im­prove pro­gres­sion-free sur­vival com­pared to plat­inum-based chemother­a­py. The GY004 tri­al re­cruit­ed pa­tients with plat­inum-sen­si­tive re­lapsed ovar­i­an can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER